• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1276942 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ J; e  c- z+ ]NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
- o* ]& }. }* G/ B& ~. ~+ Author Affiliations
' p1 p/ l" R! |* L  h- l1 R! c4 l2 A4 s( a& W: D8 y/ T. j
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
% K! f% C; ~. C3 c* H3 G2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & E+ M2 F$ ?3 T( I
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 S3 U2 g6 H* E0 ~+ u) T
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
% G1 y- |2 m2 X5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
( J' t! R2 L( Y3 e+ Y6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 2 H1 p2 E9 _1 J2 V) a! |( r, c
7Kinki University School of Medicine, Osaka 589-8511, Japan
0 C! R2 u+ G; O8Izumi Municipal Hospital, Osaka 594-0071, Japan - [& e4 _5 e- \1 X+ b
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan : n+ l% y8 E0 S& p1 a, |5 b7 T; t" b  K
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
3 X" h% `& x: C1 W" S2 hAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
* v1 C, A, p+ ~1 y
# ^8 h0 l/ c+ M
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
) ~; s, B: Q& _* P
( R4 ~: B* g6 V5 P5 k. RAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato . ]: M) O, o) d8 m5 l4 b$ b  w
" {6 P4 v/ L0 p* @1 h
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  3 [# n( P7 R3 \

3 Z1 q! b6 ^7 \* A5 ]- J: HPublished online on: Thursday, December 1, 2011 . j' q. U7 R8 @6 O+ ?
3 s4 L8 D5 M0 }( X& ?1 L8 ?+ u2 M
Doi: 10.3892/ol.2011.507
3 x( v! k1 H8 M  Y4 ?
; S: h9 i$ ~) `8 t7 x3 YPages: 405-410 0 L' N3 W* e: F- F7 U
6 i8 `8 P3 T, H3 P: e& g5 }
Abstract:
2 z! |7 w7 Y- S: ?: `$ \S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.- t3 I" N, |# m$ ~$ \& g/ p9 L4 }! q
( R" B% L# j! g1 s$ A) J
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
# C$ \8 V. l" ]( f/ ~F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 8 z# j, H" f; D( Q: ?
+ Author Affiliations8 R3 u( T! [5 o+ B1 u0 g
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
+ z" }, x  e9 {  w$ y5 s( R2Department of Thoracic Surgery, Kyoto University, Kyoto ( V7 }  Q; I! |5 `
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan - s7 [0 b' H. J
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
) o5 A4 ?+ _! z0 m. oReceived September 3, 2010.
5 o- N  K( c! H( K. fRevision received November 11, 2010. / g  [7 o. q8 E5 ?
Accepted November 17, 2010.
) s9 N0 d7 {. I1 z' GAbstract
  ]; z% F) X& kBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. ( E; f2 V/ T( @2 S. T, `- Y
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
1 M1 U6 U+ t% C3 pResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
0 H9 ?7 ~2 o% ]; A, \% qConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
& X4 C! {5 w# p7 ^6 q
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
6 T1 [  e' k$ x- D0 ^. d今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
" Q! f; G7 }/ K+ U; v/ l- r
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy1 p6 J- \* v4 q" U$ x& k
http://clinicaltrials.gov/ct2/show/NCT01523587
- z( W4 a+ d5 r4 D- n/ @2 g9 A5 X' q- u" G7 c. q- n( c
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
- ~% r1 u# L$ ^! ~6 i; x0 m% Dhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
2 R$ v$ h( @/ T
& {6 U7 s) G# T  y5 h从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
$ n$ ?+ _( D5 U+ E- s$ U至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
; v; U9 E6 J! ?! D7 G从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
, H# o5 V- A9 x8 V- m至今为止,未出 ...

, `9 B3 D2 N3 x0 m( B没有副作用是第一追求,效果显著是第二追求。
% P. p, |9 `# m- z6 y& B( T不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表